Drugmakers Zydus Cadila said it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients’ company is going to start phase 3 trials with PegiHep soon. The trials will start in December in the start it will be conducted on 250 patients across 20-25centres in India.The company is going to start further trials a similar phase 2 in Mexico and the US Food and Drug Administration (USFDA) to start the Investigational New Drug(IND) application for Pegylated Interferon alpha-2b in order to initiate appropriate clinical trials in US.
In recent years, India has made significant strides in the fight against cancer, with an…
As we age, our cognitive abilities naturally decline, but diet has emerged as a key…
In a significant move toward revolutionizing patient care, a panel discussion on Artificial Intelligence (AI)-based…
Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide. Early…
Airport Proximity: Can living near an airport increase your risk of a heart attack? A…
Antimicrobial resistance (AMR), the ability of bacteria, fungi, and parasites to resist the effects of…